ArticleJournal of Cancer2019
Comparison of Clinicopathological Features and Prognosis between
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2021Pooled it
- The clinicoradiological and pathological-molecular characteristics associated with spread through air spaces in stage IA invasive lung adenocarcinoma.Insights into imaging · 2026Article
- Necessity of systematic lymph node dissection in early-stage pure solid lung cancer adjacent to the mediastinum.Updates in surgery · 2026Article
- Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations.Molecular oncology · 2025Article
- Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.World journal of surgical oncology · 2025Article
- Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma.Frontiers in oncology · 2025Article
- Risk Stratification and Adjuvant Chemotherapy for High-Risk Stage IA Lung Adenocarcinoma: The Unmet Needs.Thoracic cancer · 2025Article
- Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.Neoplasia (New York, N.Y.) · 2024Article
- A validated model to predict spread through air space in lung adenocarcinoma.Journal of thoracic disease · 2024Article
- An eleven-gene risk model associated with lymph node metastasis predicts overall survival in lung adenocarcinoma.Scientific reports · 2023Article
- EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.International journal of molecular sciences · 2022Article
- [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- [Relationship between EGFR, ALK Gene Mutation and Imaging and Pathological Features in Invasive Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.Current oncology (Toronto, Ont.) · 2021Review
- Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.Translational cancer research · 2021Review
- An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.Journal of cancer research and clinical oncology · 2021Article
- Assessment of relationships among clinicopathological characteristics, morphological computer tomography features, and tumor cell proliferation in stage I lung adenocarcinoma.Journal of thoracic disease · 2021Article
- Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.Scientific reports · 2021Article
- Four long noncoding RNAs act as biomarkers in lung adenocarcinoma.Open medicine (Warsaw, Poland) · 2021Article
- Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma.Journal of Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of mutations in key oncogenes have been identified as important for the initiation and maintenance of lung adenocarcinoma (LAC). This study elucidated the prevalence and prognostic significance of mutations in the epidermal growth factor receptor gene ( PATIENTS AND
methodsWe retrospectively analyzed 675 consecutive patients who underwent radical resection at a single institution. We concurrently analyzed mutations in
result
conclusionClinicopathological features of LAC with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.